TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04539756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
Study: NCT04272957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306
Description: HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study: NCT00621998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 0.5-6 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 2.5-20 mg/day
Study: NCT01558713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- Fentanyl - Normal Saline
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine-Fentanyl-Normal Saline
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine- Fentanyl- Normal Saline
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Fentanyl
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + Fentanyl
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine + Fentanyl
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
Study: NCT01158105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
Study: NCT01554163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Description: Etoricoxib 30 mg tablet once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg
Description: Celecoxib 200 mg once daily for 12 weeks
Study: NCT03443258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needs assesment tool integrated in nursing consultation.
Description: Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
Study: NCT02572960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 2 weeks of Valsartan 80 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 2 weeks of Valsartan 80 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Valsartan
Description: 2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 12 weeks of daily cholecalciferol treatment, 70 microgram per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 12 weeks of daily cholecalciferol treatment, 70 microgram per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cholecalciferol
Description: 12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
Study: NCT02273765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + lamivudine + raltegravir
Description: In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + lamivudine + efavirenz
Description: In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.
Study: NCT03051373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel, S-1
Description: Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, cisplatin
Description: Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
Study: NCT03867968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS Intervention
Description: Web-based training for family member.
Study: NCT00673556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Intramuscular (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Intramuscular (IM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular (IM)
Study: NCT04315116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate
Description: a single oral dose of pyrotinib maleate on day 1 \& day10 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg bid from day 7 to day 13
Study: NCT01017263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lis-dexamphetamine
Description: Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
Study: NCT00527150

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
Study: NCT04158271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Description: In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Description: In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Description: In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube Leackage
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube Leackage
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube Leackage
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
Study: NCT03655665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin otic solution
Description: Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
Study: NCT04055610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training using H-MEX exoskeleton
Description: Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
Study: NCT04296045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCE
Description: Ingestion of 15g MCE in water after min 10 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCE
Description: Ingestion of 15g MCE in water after min 10 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Ingestion of 15g glucose in water after min 10 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Ingestion of 15g glucose in water after min 10 hours of fasting
Study: NCT01640171

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Xylocaine 2% Injectable Anesthetic
Description: xylocaine 2% injection 0.1 cc

Intervention type: DRUG
Group type: OTHER
Intervention: Proparacaine Hydrochloride 0.5% Drop
Description: Topical drop given first to the treated eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Tetravisc 0.5% Gel
Description: Gel applied to eye 3 times prior to treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Acuvail
Description: Anti-inflammatory drop given after treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Intra-vitreal Anti-VEGF Drug
Description: Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
Study: NCT00796393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033
Description: 1 pill per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033
Description: 1 pill per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch of potato
Description: 1 pill per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch of potato
Description: 1 pill per day for 12 weeks
Study: NCT04394312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent PLAYSHOP
Description: The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support.
Study: NCT03297398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group-1 (15mg, OPK-88004)
Description: 15mg, OPK-88004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group-2 (25 mg,OPK-88004)
Description: 25 mg,OPK-88004

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03137706

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo fresh tumor tissue collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Procedure
Description: Tissue stiffness and cell viability analysis
Study: NCT01728623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080 capsule
Description: E7080 is administered as continuous once daily dosing in an uncontrolled manner
Study: NCT02957695

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Neurofeedback
Description: The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-Neurofeedback
Description: The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH.
Study: NCT03443414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 suspension
Description: A dual PDE3/PDE 4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 suspension
Description: A dual PDE3/PDE 4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 suspension
Description: A dual PDE3/PDE 4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 suspension
Description: A dual PDE3/PDE 4 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT00887029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DuoTrav (travoprost-timolol ophthalmic drops)
Description: topical ophthalmic drops instilled 1 drop daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalacom (latanoprost-timolol ophthalmic drops)
Description: topical ophthalmic drops instilled 1 drop daily
Study: NCT02676609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated carbohydrate and meal insulin dose computing
Description: Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated carbohydrate and meal insulin dose computing
Description: Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
Study: NCT03499262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Social ABCs
Description: Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
Study: NCT03867968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traumatic Brain Injury website for family members.
Study: NCT01351948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + AMA1-C1/Alhydrogel®
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1 + MVA AMA1
Description: 5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
Study: NCT05003830

Intervention type: DEVICE
Intervention: PET/MR
Description: 18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.

Intervention type: DEVICE
Intervention: PET/MR
Description: 18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
Study: NCT03668522

Intervention type: OTHER
Intervention: Genetic testing
Description: To determine whether H3F3AK27M exist in spinal glioma

Intervention type: OTHER
Intervention: Genetic testing
Description: To determine whether H3F3AK27M exist in spinal glioma
Study: NCT01584505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 + CHF5992 dose 1 BID
Description: CHF1535 + CHF5992 dose 1 BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 + CHF5992 dose2 BID
Description: CHF1535 + CHF5992 dose 2 BID for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535 daily dose
Description: CHF1535 daily dose for 14 days
Study: NCT01841801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Adhesive Patch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Thermal Adhesive Patch

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study: NCT03439410

Intervention type: OTHER
Intervention: Clinical Complexity Index
Description: Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.

Intervention type: OTHER
Intervention: Clinical Complexity Index
Description: Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
Study: NCT00441987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-953
Study: NCT03890978

Intervention type: OTHER
Group type: OTHER
Intervention: promotional Exclusive breastfeeding text messages
Description: promotional Exclusive breastfeeding text messages will be send to women via mobile phone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: promotional Exclusive breastfeeding text messages
Description: promotional Exclusive breastfeeding text messages will be send to women via mobile phone